New concepts in antimicrobial resistance in cystic fibrosis respiratory infections

Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt

Dokumenter

  • Fulltext

    Forlagets udgivne version, 1,38 MB, PDF-dokument

In this review, we summarize the main points that were raised and highlighted during the pre-conference meeting to the 17th European Cystic Fibrosis Society Basic Science Conference, held from 30 March to 2 April, 2022 in Albufeira, Portugal. Keynote lectures provided an update on the latest information regarding the phenomenon of antimicrobial resistance (AMR) in cystic fibrosis (CF). Traditional themes such as in vitro antibiotic susceptibility testing and its clinical value, AMR evolution in persistent Pseudomonas aeruginosa infection and the impact of biofilm on AMR were discussed. In addition, the report gives an overview on very recent AMR-related topics that include an ecological view of AMR in CF lung, referred to as resistome, and novel anti-infective approaches in preclinical or early clinical research such as antibiofilm drugs and bacteriophages.

OriginalsprogEngelsk
TidsskriftJournal of Cystic Fibrosis
Vol/bind21
Udgave nummer6
Sider (fra-til)937-945
Antal sider9
ISSN1569-1993
DOI
StatusUdgivet - 2022

Bibliografisk note

Funding Information:
We thank the CF patient organisations from France (Vaincre la Mucoviscidose), The Netherlands (Nederlandse Cystic Fibrosis Stichting), Belgium (Mucovereniging), Italy (Lega Italiana Fibrosi Cistica), United Kingdom (CF Trust) and Germany (Mukoviszidoze e.V.) and to the European CF Society for organizing the pre-conference meeting. We are most grateful to Sylvia Hafkemeyer, David Debisshop and Christine Dubois for their excellent assistance in preparation of the symposium. We acknowledge the help from Dr. R. La Rosa at the Novo Nordisk Foundation Center for Biosustainability (Kgs. Lyngby, Denmark) for designing and creating the Figure 2 . PD is supported by the National Institute of Virology and Bacteriology (Programme EXCELES, ID Project No. LX22NPO5103 ) - Funded by the European Union - Next Generation EU. RC is supported by Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Ciencia, Innovación y Universidades (Ref. CIBERINFEC CB21/13/00084 and PI19-01043). JCD is supported by the National Institutes of Health Research through the Imperial Biomedical Research Centre, the Royal Brompton Clinical Research Facility and a Senior Investigator Award. LRH is supported by the National Institutes of Health ( K24HL141669 ) and the Cystic Fibrosis Foundation ( HOFFMA20Y2-SVC ). HKJ is supported by a Challenge grant ( NNF19OC0056411 ) and a research grant ( NNF18OC0052776 ) from the Novo Nordisk Foundation .

Funding Information:
P.D. reports personal fees from Vertex Pharmaceuticals, Chiesi CZ and I.T.A.-Intertact outside the submitted work. P-R. B. reports grants and/or personal fees from Vertex Pharmaceuticals, GlaxoSmithKline, AstraZeneca, Chiesi, Insmed, Viatris, Zambon, Pari, Pfizer, Boehringer Ingelheim outside the submitted work. J.C.D. reports grants and/or personal fees from UK CF Trust, CF Foundation, CF Ireland, EPSRC, Vertex Pharmaceuticals, Boehringer Ingelheim, Eloxx, Algipharma, Abbvie, Arcturus, Enterprise Therapeutics, Recode, LifeArc, Genentech outside the submitted work. All other authors have no conflicts of interest.

Funding Information:
We thank the CF patient organisations from France (Vaincre la Mucoviscidose), The Netherlands (Nederlandse Cystic Fibrosis Stichting), Belgium (Mucovereniging), Italy (Lega Italiana Fibrosi Cistica), United Kingdom (CF Trust) and Germany (Mukoviszidoze e.V.) and to the European CF Society for organizing the pre-conference meeting. We are most grateful to Sylvia Hafkemeyer, David Debisshop and Christine Dubois for their excellent assistance in preparation of the symposium. We acknowledge the help from Dr. R. La Rosa at the Novo Nordisk Foundation Center for Biosustainability (Kgs. Lyngby, Denmark) for designing and creating the Figure 2. PD is supported by the National Institute of Virology and Bacteriology (Programme EXCELES, ID Project No. LX22NPO5103) - Funded by the European Union - Next Generation EU. RC is supported by Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Ciencia, Innovación y Universidades (Ref. CIBERINFEC CB21/13/00084 and PI19-01043). JCD is supported by the National Institutes of Health Research through the Imperial Biomedical Research Centre, the Royal Brompton Clinical Research Facility and a Senior Investigator Award. LRH is supported by the National Institutes of Health (K24HL141669) and the Cystic Fibrosis Foundation (HOFFMA20Y2-SVC). HKJ is supported by a Challenge grant (NNF19OC0056411) and a research grant (NNF18OC0052776) from the Novo Nordisk Foundation.

Publisher Copyright:
© 2022

ID: 328732670